Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 66

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 66
---
 next annual stockholder meeting, subject to the director’s continuous service as of such date, and will vest in full upon a change of control. The term of each option will be ten years, subject to earlier termination as provided in the 2019 Plan.

Under the April 2024 Non-Employee Director Compensation Policy, the Company adopted a deferral program for Initial Director RSU Grants and Annual Director RSU Grants to non-employee directors. Such deferral program allows non- employee directors to defer receipt of shares that may vest under future Initial Director RSU Grants and Annual Director RSU Grants until the earlier to occur of (a) 60 days following separation from service or (b) immediately prior to a change in control.

In April 2025, our Board, upon the recommendation of the Compensation Committee, adopted a revised non-employee director compensation policy effective as of April 2, 2025 (the “ April 2025 Non-Employee Director Compensation Policy ”), which applied for the second quarter of 2025 onwards. The April 2025 Non-Employee Director Compensation Policy made no changes to the April 2024 Non-Employee Director Compensation Policy, except:

• the additional annual cash retainer for services as a member of the Audit Committee increased from $10,000 to $12,500;

• the additional annual cash retainer for services as Chair of the Audit Committee increased from $20,000 to $25,000;

• the aggregate grant date fair value of an Initial Director Grant increased from $450,000 to $550,000; and

• the aggregate grant date fair value of an Annual Director Grant increased from $300,000 to $350,000.

#### Mirum Pharmaceuticals2025 Proxy Statement55

### TABLE OF CONTENTS
| Security Ownership of Certain Beneficial Owners and Management |

The following table sets forth information regarding beneficial ownership of our common stock as of February 15, 2025 (the “Measurement Date” ) by:

(i) each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;

(ii) each of our directors, including the nominees named herein;

(iii) each of our named executive officers; and

(iv) all of our current executive officers and directors as a group.

We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe